Literature DB >> 8167342

Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q21q23).

K Offit1, D C Louie, N Z Parsa, D Filippa, M Gangi, R Siebert, R S Chaganti.   

Abstract

Deletions of the long arm of chromosome 6 have been described in acute and chronic lymphocytic leukemia (ALL and CLL) and prolymphocytic leukemia (PLL), and have been associated with t(14;18)(q32;q21) in non-Hodgkin's lymphoma (NHL). Of 55 cases of small lymphocytic (sm lym) NHL, deletions of 6(q21q23) were the most common recurring cytogenetic abnormality. Among 14 sm lym NHL with del(6)(q21q23), this abnormality occurred as a solitary change in 3 cases. Each of these 3 cases, and 5 additional cases with del(6q) and other abnormalities, showed atypical larger forms with the morphologic appearance of prolymphocytes or paraimmunoblasts in the peripheral blood. In comparison, of the 11 cases without del(6q) and circulating abnormal cells, prolymphocytoid forms were observed in 4 cases (P < .001). Of the 31 sm lym without del(6q), trisomies of chromosomes 3, 12, or 18, or t(11;14)(q13;q32) occurred in greater than 10% of cases. Proliferation centers or infiltration by larger forms were observed in similar proportions of tissue sections derived from sm lym NHL with or without del(6q). The presence of the larger forms in the peripheral blood did not have an adverse prognostic impact on the survival of the del(6q) cohort, who experienced a median survival in excess of 6 years. All 14 cases of del(6q) sm lym NHL were characterized by a mature B-cell phenotype. Expression of CD11c, a feature of a CLL/PLL variant previously described, was not detected in 9 cases analyzed. In 5 cases of del(6q) sm lym NHL, no circulating abnormal lymphocytes were noted. Twelve cases presented with, or developed, clinical splenomegaly. These results suggest that deletion of a gene or genes at 6q21-23 is associated with the pathogenesis of a subset of B-cell sm lym NHL that may display larger prolymphocytoid cells in the peripheral blood, but that follows a clinical course typical of other well-differentiated lymphocytic neoplasms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8167342

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Impaired maturation of myeloid progenitors in mice lacking novel Polycomb group protein MBT-1.

Authors:  Satoko Arai; Toru Miyazaki
Journal:  EMBO J       Date:  2005-05-05       Impact factor: 11.598

2.  Karyotypic and molecular abnormalities in chronic lymphocytic leukaemia.

Authors:  C D Fegan; F E Davies
Journal:  Clin Mol Pathol       Date:  1996-08

Review 3.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

4.  Translocation detection in lymphoma diagnosis by split-signal FISH: a standardised approach.

Authors:  Anke van Rijk; David Mason; Margaret Jones; José Cabeçadas; Mateus Crespo; Juan Cruz Cigudosa; Juan Fernando Garcia; Lorenzo Leoncini; Mario Cocco; Martin-Leo Hansmann; Anja Mottok; Christiane Copie Bergman; Maryse Baia; Dimitra Anagnostou; Evi Pouliou; Stephen Hamilton Dutoit; Mette Hjøllund Christiansen; Tim Svenstrup Poulsen; Steen Hauge Matthiesen; Jacques van Dongen; J Han van Krieken
Journal:  J Hematop       Date:  2008-08-29       Impact factor: 0.196

5.  High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.

Authors:  Esteban Braggio; Jonathan J Keats; Xavier Leleu; Scott Van Wier; Victor Hugo Jimenez-Zepeda; Roelandt F J Schop; Marta Chesi; Michael Barrett; Alexander Keith Stewart; Ahmet Dogan; Peter Leif Bergsagel; Irene M Ghobrial; Rafael Fonseca
Journal:  Clin Lymphoma Myeloma       Date:  2009-03

6.  FISH Analysis for del6q21 and del17p13 in B-cell Chronic Lymphocytic Leukemia in Iranians.

Authors:  Hossein Teimori; Saeede Ashoori; Mohamad Taghi Akbari; Marjan Mojtabavi Naeini; Morteza Hashemzade Chaleshtori
Journal:  Iran Red Crescent Med J       Date:  2013-02-05       Impact factor: 0.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.